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In a previous study, we showed that levels of cell-free DNA (cfDNA) were significantly higher in sera of patients with hepatocellular
carcinoma (HCC) associated with hepatitis C virus (HCV) than in sera of non-HCC patients with HCV. To confirm this finding, we
analysed serum cfDNA levels in a cohort of 96 patients with HCV-related HCC and in 100 HCV carriers without known HCC. Again
we found that serum cfDNA levels were significantly higher in HCC patients than in HCV carriers (115.9±98.3 vs
34.4±40.4ngml
 1 (mean±s.d.), Po0.0001). Of 87 eligible patients who underwent curative hepatectomy, those with a high
cfDNA level had a significantly shorter overall survival (OS) time than those in whom the cfDNA level was not high. Cox
proportional hazards model showed the cfDNA level to be an independent prognostic factor for OS and cancer recurrence in distant
organs. Our results suggest that the serum cfDNA level reflects the metastatic potential of HCV-related HCC and that it can be a
useful predictive biomarker for distant metastasis after curative surgery.
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Hepatocellular carcinoma is one of the most common cancers,
with an estimated 564000 new cases registered worldwide in 2000
(Parkin et al, 2001), and it represents a major international health
problem because its incidence is increasing in many countries
(Deuffic et al, 1998; Llovet et al, 2003; El Serag, 2004). Particularly
in Europe and North America, the incidences of HCC have
increased markedly in the last decade and will increase further in
the upcoming two decades due to hepatitis C virus (HCV) infection
(Deuffic et al, 1998; El Serag, 2004). Despite much effort in HCC
research, the prognosis of HCC remains poor because of both a
high frequency of intrahepatic recurrence (IHR; Iizuka et al, 2003,
2004; Llovet et al, 2003) and high mortality of associated with
extrahepatic recurrence (EHR) in distant organs (Itoh et al, 2002;
Yang et al, 2007). Therefore, new non-invasive prognostic markers
are urgently needed to improve the prognosis of HCC, especially of
HCV-related HCC.
It may become possible to use serum biomarkers to screen for
HCC patients at high risk for recurrence (Mann et al, 2007). To
date, many candidate markers have been reported in relation to the
clinical outcome of HCC patients (Marrero and Lok, 2004;
Kuramitsu and Nakamura, 2006). In addition to these biomarkers,
circulating cell-free DNA (cfDNA) has attracted a great deal of
attention as an easy-to-use tool for evaluation of the malignant
potential of cancer (Gautschi et al, 2004; Umetani et al, 2006). By
means of real-time polymerase chain reaction (PCR) assay, we
found that cfDNA levels were significantly higher in sera from
patients with HCV-related HCC than in sera from HCV carriers
without known HCC (Iizuka et al, 2006a). An additional intriguing
finding was that cfDNA levels increased in parallel with tumour
dedifferentiation and were positively associated with tumour size.
Ren et al (2006) showed that levels of circulating cfDNA correlated
inversely with the prognosis of HCC, in most cases attributable to
hepatitis B virus (HBV) infection, suggesting that cfDNA may be a
robust predictive marker for the prognosis of HBV-related HCC.
However, a marker specific to HBV-related HCC may not be useful
for HCV-related HCC because there are many differences in
genetic changes and the clinical course between the two types of
HCC (Iizuka et al, 2002; Llovet et al, 2003). We were prompted to
examine whether cfDNA levels were predictive of outcomes in a
larger cohort of patients with HCV-related HCC. Our present study
showed for the first time in a large study group that the cfDNA
level in the bloodstream can function as a predictor for overall
survival (OS) and EHR in distant organs after curative hepatectomy
in patients with HCV-related HCC.
MATERIALS AND METHODS
Patients and samples
Between April 1998 and August 2006, 96 patients underwent
surgical treatment of HCC at Yamaguchi University Hospital. All
were positive for HCV antibody. Clinical characteristics of these
Received 12 June 2007; revised 12 September 2007; accepted 24
September 2007; published online 16 October 2007
*Correspondence: Dr M Oka; E-mail: 2geka-1@po.cc.yamaguchi-u.ac.jp
British Journal of Cancer (2007) 97, 1399–1403
& 2007 Cancer Research UK All rights reserved 0007– 0920/07 $30.00
www.bjcancer.com
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
spatients based on the TNM classification (Sobin and Wittekind,
2002) of the Union Internationale Contre le Cancer (UICC) are
shown in Table 1. To explore the relation between serum cfDNA
levels and patient outcomes, we excluded six patients who had any
residual tumour, and three patients who died of other disease. As a
result, the remaining 87 patients were subjected to the following
study. Patients were followed up as described previously (median
follow-up time: 39 months) (Iizuka et al, 2003; Matoba et al, 2005).
In brief, all 87 patients were followed up at least once every 3
months postoperatively by routine X-ray, ultrasonography (US),
computed tomography, or magnetic resonance imaging, levels of
serum a-fetoprotein and protein induced by vitamin K absence II
(PIVKA-II) were also measured. When tumour recurrence was
suspected, CT angiography was included as a follow-up examination.
For control, we used 100 serum samples from 100 HCV-positive
patients with chronic liver disease who were recruited from
outpatient clinics of the Yamaguchi University Graduate School of
Medicine between July 2001 and October 2006. These control
samples were selected to minimize the difference in age (66.3±7.3
vs 64.9±8.4 years (mean±s.d.), P¼0.209) between the HCC
group and the control group. Laboratory tests and imaging studies
including US and CT did not reveal any HCC in the 100 HCV-
positive patients during the median follow-up time of 18 months.
The study protocol was approved by the Institutional Review
Board for the Use of Human Subjects at the Yamaguchi University
School of Medicine, and written informed consent was obtained
from each patient.
Extraction and quantification of DNA in sera
Blood samples were collected as described previously (Iizuka et al,
2006a). After clotting, which occurred within 1h of collection,
blood samples were spun at 3000r.p.m. (1600 g) for 10min at
room temperature. Sera were stored at  801C until use. DNA was
extracted from 1ml of serum with a DNA Extractor SP Kit for
Serum and Plasma (Wako Pure Chemical Industries Ltd, Osaka,
Japan) according to the manufacturer’s instructions. DNA was
quantified as described previously (Iizuka et al, 2006a). Briefly, 1ml
of DNA solution was subjected to real-time PCR amplification for
quantitative analysis of the GSTP1 gene. Finally, we calculated the
amount of DNA on the basis of standard DNAs (leucocyte genomic
DNAs) at 16–2000ngml
 1.
Statistical analysis
Values are shown as mean±s.d. The Mann–Whitney U-test,
Student’s t-test and w
2 test were used to analyse differences in
values between two groups, and analysis of variance was used to
analyse differences between three groups. Overall survival and
disease-free survival (DFS) were determined by the Kaplan–Meier
method and analysed by log-rank test. The effect of eight
clinicopathologic factors (sex, age, cfDNA level, tumour size,
number of primary lesion, venous invasion, tumour differentiation
grade and TNM stage) on OS and EHR in distant organs was
assessed by means of the Cox proportional hazards model, hazard
ratios (HRs) and 95% confidence intervals (CIs) were calculated.
Multivariate analysis was also performed to identify independent
factors for early IHR by means of the stepwise logistic regression
model. The eight above-mentioned clinicopathologic factors were
also entered into a forward stepwise regression model. Each model
was tested for goodness of fit by –2log likelihood and w
2 in each
step. All analyses were performed with SPSS 11.0J software (SPSS
Inc., Chicago, IL, USA) run on a Windows computer. A P-value of
less than 0.05 was considered statistically significant.
RESULTS
Serum cfDNA levels were significantly higher in HCC patients
than in HCV carriers without known HCC (115.9±98.3 vs
34.4±40.4ngml
 1 (mean±s.d.), Po0.0001 by Mann–Whitney
U-test) (Figure 1). There was no significant difference in serum
cfDNA levels between the 100 HCV carriers without known HCC
and 18 healthy people or patients with benign disease who had no
HCV infection (34.4±40.4 vs 45.8±22.6ngml
 1); (data not
shown). Serum cfDNA levels were not associated with any
clinicopathologic factors in the total 96 HCC patients (Table 1).
Of the 87 patients who underwent curative hepatectomy, 35 had
no recurrence during the follow-up period and the remaining
52 had IHR. Of the 52 patients with IHR, 13 had EHR in distant
organs such as lung and bone. Given the finding that cfDNA levels
of HCV carrier without HCC are similar to those of controls
without HCV infection, to examine the relation between cfDNA
and follow-up data, we used a cfDNA cutoff value of 117.8ngml
 1,
which is equal to the meanþ2 s.d. of the control value (value in
HCV carriers without HCC). Patients with a high cfDNA level
(n¼29) had significantly shorter OS than those with a low cfDNA
level (n¼58) (P¼0.017 by log-rank test; Figure 2A). By contrast,
serum cfDNA levels were not associated with DFS (Figure 2B).
According to the multivariate Cox proportional hazards model,
cfDNA (HR, 3.4; 95% CI, 1.5–7.6; P¼0.004) and tumour size (HR,
3.8; 95% CI, 1.7–8.5; P¼0.001) were the only independent
prognostic factors for OS (Table 2). In addition, cfDNA (HR, 4.5;
95% CI, 1.3–14.9; P¼0.014) was the only independent prognostic
factor for EHR in distant organs (Table 3).
To investigate the relation between cfDNA level and early IHR
due to intrahepatic metastasis of HCC, we excluded 10 patients
Table 1 Characteristics of patients and HCCs per cfDNA level
cfDNA amount
Low
(o117.8ngml
 1)
High
(X117.8ngml
 1) P-value
Sex 0.132
Male (n¼71) 42 29
Female (n¼25) 19 6
Age (year) 0.76
o60 (n¼18) 12 6
460 (n¼78) 49 29
Tumour size 0.879
o5cm(n¼76) 48 28
45cm(n¼20) 13 7
Number of primary
lesion
0.299
Single (n¼56) 38 18
Multiple (n¼40) 23 17
Venous invasion 0.586
Negative (n¼69) 45 24
Positive (n¼27) 16 11
Tumour differentiation 0.155
Well (G1) (n¼24) 18 6
Moderately (G2)
(n¼64)
40 24
Poorly (G3) (n¼8) 3 5
UICC TNM stage 0.217
I( n¼44) 32 12
II (n¼42) 23 19
IIIA/IV (n¼10) 6 4
cfDNA¼cell-free DNA; HCV¼hepatitis C virus; HCC¼hepatocellular carcinoma.
To evaluate the high and low of cfDNA levels, we used a cutoff value of
117.8ngml
 1, which is equal to the mean+2s.d. of the control value (value in HCV
carriers without HCC).
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swho had the follow-up periods of less than 1 year after surgery.
Among the eligible 77 patients, 15 (19.5%) had early IHR within
1 year of surgery and the remaining 62 (80.5%) did not have
early IHR. Among the 62 patients, 37 had IHR 1 year or more after
surgery and 25 had no IHR during follow-up periods. The serum
cfDNA level was significantly higher in patients (n¼15) with early
IHR than in those (n¼62) without early IHR (176.3±124.8 vs
108.7±87.9ngml
 1, P¼0.017 by Student’s t-test; Figure 3). The
logistic regression model showed that tumour size (relative risk,
7.3; 95% CI, 1.9–27.7; P¼0.004) and number of primary lesions
(relative risk, 4.5; 95% CI, 1.1–17.7; P¼0.033), but not cfDNA
level, were independent risk factors for early IHR (data not
shown).
DISCUSSION
The possibility of detecting and measuring tumour-derived cfDNA
has opened a new avenue in predictive oncology (Leon et al, 1977;
Anker et al, 1999; Ziegler et al, 2002). This method provides a
non-invasive and easy-to-use tool for screening for malignancy
and predicting cancer outcomes. By means of real-time PCR, we
showed previously that cfDNA levels were significantly higher in
sera from patients with HCV-related HCC than in sera from HCV
carriers without known HCC, and the diagnostic performance of
cfDNA was superior to that of two representative HCC markers,
a-fetoprotein and PIVKA-II (Iizuka et al, 2006a). Our present
study confirmed the significantly increased levels of serum cfDNA
in a large group of patients with HCV-related HCC, suggesting that
the increase is related to progression of the disease caused by HCV
infection. Indeed, our present study identified two subgroups of
patients with HCV-related HCC: those with a high cfDNA level who
had an unfavourable outcome after curative surgery, and those
with a low cfDNA level, who had a favourable outcome. Notably,
cfDNA was the only independent prognostic factor for EHR in
distant organs in case of HCV-related HCC treated surgically.
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Figure 1 Box and whisker plot of cell-free DNA (cfDNA) levels in sera
as determined by GSTP1-specific PCR assay. Levels of cfDNA in sera were
significantly higher in hepatocellular carcinoma (HCC) patients than in
hepatitis C virus (HCV) carriers (115.9±98.3 vs 34.4±40.4ngml
 1
(mean±s.d.), Po0.0001 by Mann–Whitney U-test).
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Figure 2 Relation between serum cell-free DNA (cfDNA) levels and overall and disease-free survival (DFS) in hepatocellular carcinoma (HCC) patients.
(A) cfDNA levels and overall survival (OS). (B) cfDNA levels and DFS. Note that patients with a high cfDNA level had significantly shorter OS than did
those with a low level of cfDNA (n¼58) (P¼0.017 by log-rank test). By contrast, serum cfDNA levels were not related to DFS.
Table 2 Independent risk factors for OS
Variable HR (95% CI) P-value
cfDNA 0.004
Low
a 1
High
a 3.4 (1.5–7.6)
Tumour size 0.001
Less than 5cm 1
More than or equal to 5cm 3.8 (1.7–8.5)
cfDNA¼cell-free DNA; CI¼confidence interval; HCC¼hepatocellular carcinoma;
HR¼hazard ratio; OS¼overall survival.
aLow, less than 117.8ngml
 1; high, more
than or equal to 117.8ngml
 1.
Table 3 Independent risk factors for cancer recurrence in distant organs
Variable HR (95% CI) P-value
cfDNA 0.014
Low
a 1
High
a 4.5 (1.3–14.9)
Tumour differentiation grade 0.069
G1
b 1
G2+G3
b 2.5 (0.9–7.0)
cfDNA¼cell-free DNA; CI¼confidence interval; HCC¼hepatocellular carcinoma;
HR¼hazard ratio.
aLow, less than 117.8ngml
 1; high, more than or equal to
117.8ngml
 1.
bG1, well-differentiated HCC; G2, moderately differentiated HCC; G3,
poorly differentiated HCC.
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sRecurrence of HCC is quite complicated. There are at least three
representative modes of postoperative recurrence, early and late
IHRs appearing in the remnant liver and EHR appearing in distant
organs such as bone and lung. Among the three types of
recurrence, late IHR is a de novo primary tumour rather than a
metastatic tumour, and it accounts for the majority of HCC
recurrences 3 years or more after surgery (Kumada et al, 1997),
suggesting that it has less influence on patient survival. The finding
that our cohort included many patients with late IHR might
account for the lack of association between cfDNA levels and DFS
in patients with HCV-related HCC. In contrast, our univariate
analysis showed increased levels of cfDNA in HCC patients with
early IHR. Most early IHRs can be attributed to intrahepatic
metastasis of cancer cells and are detected in 30–50% of patients
within 1 or 2 years after surgery, limiting the potential for surgical
cure of HCC (Tung-Ping Poon et al, 2000; Iizuka et al, 2003; Llovet
et al, 2003; Matoba et al, 2005; Portolani et al, 2006). Thus, the
increased levels of serum cfDNA are related to the high metastatic
potential, but not to the appearance of de novo tumour, of this type
HCC.
Much effort has been devoted to developing predictive makers
for early IHR. Some recent molecular profiling studies (Iizuka
et al, 2003, 2004; Kurokawa et al, 2004) raised the possibility of
accurately predicting early IHR in a cohort of patients with HCC,
most of which were HCV-related HCCs. Predictive systems that are
developed will enable to accurately detect patients at high risk for
early IHR, but there might be many problems to solve before these
markers can be applied to daily clinical practice (Iizuka et al,
2004). Thus far, there have been few reports on a predictor for
EHR after surgery, although several studies have identified several
key genes or gene products related to distant metastasis
(Schimanski et al, 2006; Iizuka et al, 2006b). It was reported that
HCC recurred in distant organs in only 3 (7%) of 42 patients who
underwent liver transplantation, a radical curative treatment
strategies (Nart et al, 2003). A recent large study by Yang et al
(2007) showed that, among 348 HCC patients who underwent
hepatectomy, 47 (13.5%) had EHR during the follow-up period of
4.8±3.7 years. Thus, the frequency of EHR is lower than that
of early IHR; however, once HCC progresses to EHR, it is difficult
to control the lesions in most cases because of the limited
resectability. Indeed, the frequency of death due to respiratory
failure resulting from metastasis of HCC to the lung has increased
over the last 30 years in the Japanese population (Itoh et al, 2002).
In this regard, our present finding that a patient with a high level
of cfDNA has 4.5-fold increased risk for EHR in distant organs may
be clinically useful. Such a robust predictive system is urgently
needed to screen for patients who will develop EHR.
Taken together, our data suggest that serum cfDNA levels could
serve as a useful tool for prediction of EHR after curative surgery
in patients with HCV-related HCC. However, it is unlikely that
cfDNA alone will be effective in predicting EHR in more global
cases. A large training-validation study is needed to construct a
robust predictor made up of multiple factors in which cfDNA
might play a central role. In addition, identifying and quantifying
genetic changes in circulating cfDNAs specific to HCV-related
HCC will allow us to determine metastatic potential preoperatively
on an individual basis.
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